These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 24582986)

  • 1. Fragment-based discovery of potent inhibitors of the anti-apoptotic MCL-1 protein.
    Petros AM; Swann SL; Song D; Swinger K; Park C; Zhang H; Wendt MD; Kunzer AR; Souers AJ; Sun C
    Bioorg Med Chem Lett; 2014 Mar; 24(6):1484-8. PubMed ID: 24582986
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of potent Mcl-1/Bcl-xL dual inhibitors by using a hybridization strategy based on structural analysis of target proteins.
    Tanaka Y; Aikawa K; Nishida G; Homma M; Sogabe S; Igaki S; Hayano Y; Sameshima T; Miyahisa I; Kawamoto T; Tawada M; Imai Y; Inazuka M; Cho N; Imaeda Y; Ishikawa T
    J Med Chem; 2013 Dec; 56(23):9635-45. PubMed ID: 24215352
    [TBL] [Abstract][Full Text] [Related]  

  • 3. De novo design, synthesis and evaluation of benzylpiperazine derivatives as highly selective binders of Mcl-1.
    Ding X; Li Y; Lv L; Zhou M; Han L; Zhang Z; Ba Q; Li J; Wang H; Liu H; Wang R
    ChemMedChem; 2013 Dec; 8(12):1986-2014. PubMed ID: 24124106
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, synthesis and evaluation of marinopyrrole derivatives as selective inhibitors of Mcl-1 binding to pro-apoptotic Bim and dual Mcl-1/Bcl-xL inhibitors.
    Li R; Cheng C; Balasis ME; Liu Y; Garner TP; Daniel KG; Li J; Qin Y; Gavathiotis E; Sebti SM
    Eur J Med Chem; 2015 Jan; 90():315-331. PubMed ID: 25437618
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of 2-Indole-acylsulfonamide Myeloid Cell Leukemia 1 (Mcl-1) Inhibitors Using Fragment-Based Methods.
    Pelz NF; Bian Z; Zhao B; Shaw S; Tarr JC; Belmar J; Gregg C; Camper DV; Goodwin CM; Arnold AL; Sensintaffar JL; Friberg A; Rossanese OW; Lee T; Olejniczak ET; Fesik SW
    J Med Chem; 2016 Mar; 59(5):2054-66. PubMed ID: 26878343
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent Advances in Cancer Drug Development: Targeting Induced Myeloid Cell Leukemia-1 (Mcl-1) Differentiation Protein.
    Abid M; Sonawane YA; Contreras JI; Rana S; Natarajan A
    Curr Med Chem; 2017; 24(40):4488-4514. PubMed ID: 28901269
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of novel biaryl sulfonamide based Mcl-1 inhibitors.
    Follows B; Fessler S; Baumeister T; Campbell AM; Zablocki MM; Li H; Gotur D; Wang Z; Zheng X; Molz L; Nguyen C; Herbertz T; Wang L; Bair K
    Bioorg Med Chem Lett; 2019 Aug; 29(16):2375-2382. PubMed ID: 31235261
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of potent myeloid cell leukemia 1 (Mcl-1) inhibitors using fragment-based methods and structure-based design.
    Friberg A; Vigil D; Zhao B; Daniels RN; Burke JP; Garcia-Barrantes PM; Camper D; Chauder BA; Lee T; Olejniczak ET; Fesik SW
    J Med Chem; 2013 Jan; 56(1):15-30. PubMed ID: 23244564
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular dynamics study of small molecule inhibitors of the Bcl-2 family.
    Acoca S; Cui Q; Shore GC; Purisima EO
    Proteins; 2011 Sep; 79(9):2624-36. PubMed ID: 21721047
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of tricyclic indoles that potently inhibit Mcl-1 using fragment-based methods and structure-based design.
    Burke JP; Bian Z; Shaw S; Zhao B; Goodwin CM; Belmar J; Browning CF; Vigil D; Friberg A; Camper DV; Rossanese OW; Lee T; Olejniczak ET; Fesik SW
    J Med Chem; 2015 May; 58(9):3794-805. PubMed ID: 25844895
    [TBL] [Abstract][Full Text] [Related]  

  • 11. From meiogynin A to the synthesis of dual inhibitors of Bcl-xL and Mcl-1 anti-apoptotic proteins.
    Desrat S; Remeur C; Gény C; Rivière G; Colas C; Dumontet V; Birlirakis N; Iorga BI; Roussi F
    Chem Commun (Camb); 2014 Aug; 50(62):8593-6. PubMed ID: 24956071
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interdiction at a protein-protein interface: MCL-1 inhibitors for oncology.
    Li K
    Bioorg Med Chem Lett; 2021 Jan; 32():127717. PubMed ID: 33253879
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pro-apoptotic meiogynin A derivatives that target Bcl-xL and Mcl-1.
    Desrat S; Pujals A; Colas C; Dardenne J; Gény C; Favre L; Dumontet V; Iorga BI; Litaudon M; Raphaël M; Wiels J; Roussi F
    Bioorg Med Chem Lett; 2014 Nov; 24(21):5086-8. PubMed ID: 25266781
    [TBL] [Abstract][Full Text] [Related]  

  • 14. First evidence that oligopyridines, α-helix foldamers, inhibit Mcl-1 and sensitize ovarian carcinoma cells to Bcl-xL-targeting strategies.
    Gloaguen C; Voisin-Chiret AS; Sopkova-de Oliveira Santos J; Fogha J; Gautier F; De Giorgi M; Burzicki G; Perato S; Pétigny-Lechartier C; Simonin-Le Jeune K; Brotin E; Goux D; N'Diaye M; Lambert B; Louis MH; Ligat L; Lopez F; Juin P; Bureau R; Rault S; Poulain L
    J Med Chem; 2015 Feb; 58(4):1644-68. PubMed ID: 25585174
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery and development of substituted tyrosine derivatives as Bcl-2/Mcl-1 inhibitors.
    Liu R; Liu L; Liu T; Yang X; Wan Y; Fang H
    Bioorg Med Chem; 2018 Sep; 26(17):4907-4915. PubMed ID: 30170927
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structure-guided design of a series of MCL-1 inhibitors with high affinity and selectivity.
    Bruncko M; Wang L; Sheppard GS; Phillips DC; Tahir SK; Xue J; Erickson S; Fidanze S; Fry E; Hasvold L; Jenkins GJ; Jin S; Judge RA; Kovar PJ; Madar D; Nimmer P; Park C; Petros AM; Rosenberg SH; Smith ML; Song X; Sun C; Tao ZF; Wang X; Xiao Y; Zhang H; Tse C; Leverson JD; Elmore SW; Souers AJ
    J Med Chem; 2015 Mar; 58(5):2180-94. PubMed ID: 25679114
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of potent and selective benzothiazole hydrazone inhibitors of Bcl-XL.
    Sleebs BE; Kersten WJ; Kulasegaram S; Nikolakopoulos G; Hatzis E; Moss RM; Parisot JP; Yang H; Czabotar PE; Fairlie WD; Lee EF; Adams JM; Chen L; van Delft MF; Lowes KN; Wei A; Huang DC; Colman PM; Street IP; Baell JB; Watson K; Lessene G
    J Med Chem; 2013 Jul; 56(13):5514-40. PubMed ID: 23767404
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, synthesis, and activity evaluation of broad-spectrum small-molecule inhibitors of anti-apoptotic Bcl-2 family proteins: characteristics of broad-spectrum protein binding and its effects on anti-tumor activity.
    Zheng CH; Yang H; Zhang M; Lu SH; Shi D; Wang J; Chen XH; Ren XH; Liu J; Lv JG; Zhu J; Zhou YJ
    Bioorg Med Chem Lett; 2012 Jan; 22(1):39-44. PubMed ID: 22172701
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of the stereochemical structures of 2H-thiazolo[3,2-a]pyrimidine compounds and their binding affinities for anti-apoptotic Bcl-2 family proteins.
    Xu Y; Zhou M; Li Y; Li C; Zhang Z; Yu B; Wang R
    ChemMedChem; 2013 Aug; 8(8):1345-52. PubMed ID: 23794243
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of a potent inhibitor of the antiapoptotic protein Bcl-xL from NMR and parallel synthesis.
    Petros AM; Dinges J; Augeri DJ; Baumeister SA; Betebenner DA; Bures MG; Elmore SW; Hajduk PJ; Joseph MK; Landis SK; Nettesheim DG; Rosenberg SH; Shen W; Thomas S; Wang X; Zanze I; Zhang H; Fesik SW
    J Med Chem; 2006 Jan; 49(2):656-63. PubMed ID: 16420051
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.